OptiNose, Inc. in brief
OptiNose, Inc. is an unlisted company in the Pharmaceutical industry, based in Pennsylvania, USA. It was founded in 2010. In the year to Dec 2020 it had sales of $49 M and a net loss of $100 M.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
OptiNose, Inc. timeline
- 2010
- 🏁· approximateFounded
- 2017
- 🔔· approximateInitial public offering on Nasdaq
Events of OptiNose, Inc. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about OptiNose, Inc.
- Acquisitions and changes
- No longer listed: ticker OPTN is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).
Market cap history
World rank over time
Rank in USA: #2,652 (Jan 2020) · #3,180 (Jan 2021) · #4,121 (Jan 2022) · #3,739 (Dec 2022) · #3,960 (Jul 2023) · #3,502 (Jan 2024)
Annual results
- Revenue
- $49 M
- Operating income
- —
- Net income
- $-100 M
Dec-2020 ending year
Markets and events: OptiNose, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2025-05-20 23:50 UTC, code D, resumed 04:00 UTC
- 2025-03-04 14:30 UTC, code LUDP, resumed 14:35 UTC
- 2024-12-31 15:19 UTC, code LUDP, resumed 15:24 UTC
- 2024-12-31 00:50 UTC, code T3, resumed 14:00 UTC
Fails to deliver
- : 59 shares at $9.10
- : 1,354 shares at $9.00
- : 909 shares at $9.15
- : 5 shares at $9.15
- : 807 shares at $9.14
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
How OptiNose, Inc. compares in Pharmaceutical
- Revenue$49 M · higher than 15% of 324
- Net margin-203.1% · higher than 2% of 313
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| OptiNose, Inc.🇺🇸 | $135 M | — | -203.1% | — |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Eli Lilly and Company$1.20 T
- Johnson & Johnson$652.5 B
- AbbVie Inc.$514.0 B
- Roche Holding AG$370.3 B
- Merck & Co., Inc.$359.8 B
- Novartis AG$286.8 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- Dec-2020 ending year
- Balance sheet:
- Dec-2020 ending year
- Profile updated:
- Nov 14, 2026
Figures from value.today research.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at OptiNose, Inc.? Verify and update this profile — free
Show OptiNose, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.